Aytu BioPharma Inc (NASDAQ: AYTU) is a specialty pharmaceutical company that develops and commercializes prescription products focused on attention-deficit/hyperactivity disorder (ADHD). Revenue comes from product sales of FDA-approved branded pharmaceuticals, primarily the ADHD treatments Adzenys XR-ODT and Cotempla XR-ODT, sold to patients through retail pharmacy channels. The company generated net revenue of $66.4 million in FY2025 (year ended June 30, 2025), up from $65.2 million in FY2024, but reported a net loss from continuing operations of $14.2 million in FY2025. Gross profit declined to $45.8 million in FY2025 from $49.1 million in FY2024, reflecting higher cost of goods sold following the transfer of Adzenys and Cotempla manufacturing to a third-party facility. As of June 30, 2025, the company employed 83 people, with 52 engaged in commercial activities. Aytu carries interest-bearing debt, recorded $3.7 million in interest expense in FY2025, and faces generic competition risk, including a Paragraph IV certification filed by Granules Pharmaceuticals in October 2024 targeting Adzenys patents.

Revenue model

Transactional product sales of branded prescription ADHD medications through retail pharmacy and third-party logistics channels. No disclosed subscription or royalty revenue streams from continuing operations.

Products and services

Adzenys XR-ODT (amphetamine extended-release orally disintegrating tablet) and Cotempla XR-ODT (methylphenidate extended-release orally disintegrating tablet), both FDA-approved ADHD treatments targeting pediatric patients. Manufacturing transferred to a U.S.-based third-party contract manufacturer in Q4 FY2024.

Customers and end markets

Pediatric ADHD patients and their prescribing physicians in the United States. Products distributed through third-party logistics firms to retail pharmacies. No specific customer concentration figures disclosed in the excerpts.

Value-chain role

Branded pharmaceutical commercialization company. Outsources manufacturing to third-party contract manufacturers. Maintains patent portfolio and has filed infringement litigation, including a December 2024 suit against Granules Pharmaceuticals in the U.S. District Court for the District of Delaware.

Geographic exposure

United States only, based on disclosed operations and regulatory framework. No material sales or operations outside the U.S. noted in the excerpts.

Competitors

Granules Pharmaceuticals

Source: SEC 10-K, filed 2025-09-23

Industry: Pharmaceutical Preparations Peers: AGILE THERAPEUTICS INC Barrel Energy Inc. Cingulate Inc Hoth Therapeutics Inc Jaguar Health Inc Johnson & Johnson Petros Pharmaceuticals Inc Pulmatrix Inc Weed Inc Virpax Pharmaceuticals, Inc.